Merck has Requested Re-examination of the CHMP Opinion for Erbitux in Non-Small Cell Lung Cancer
Merck KGaA announced that it has requested re-examination of the negative opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), for the use of Erbitux® (cetuximab) in combination with platinum-based chemotherapy for the first-line treatment of patients with non-small cell lung cancer (NSCLC). Taking the opinion seriously Merck will work closely with the CHMP to unravel the value of Erbitux for patients benefit most.
The decision to request re-examination follows consultation with key stakeholders in the NSCLC treatment community, coupled with Merck’s confidence in the clinical data supporting Erbitux in this potential indication.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
1,4-Dichlorobenzene

ZEISS and RIKEN Innovation establish partnership in bioengineering and data management - Synergizing RIKEN's excellence in basic research in bioengineering with ZEISS's expertise in imaging and sensing
H1_antihistamine
